Research account from Biocentric’s published case study. Findings are reported for the methods described; limitations are noted below.
Background
Tyrosine kinase 2 (TYK2) was the target for a virtual screening study using an ultra-large chemical database. The project compared Biocentric’s pipeline with an established docking method.
Research objective
Identify potential TYK2 inhibitors in ZINC20, described in the source as approximately 900 million compounds; benchmark the screening pipeline with 20 known active compounds; and compare ranking performance with AutoDock Vina.
Screening and benchmark design
Twenty known TYK2-binding compounds were included as benchmarks. Biocentric screened the library and evaluated where those actives ranked in a final hit list described as 500,000 compounds.
The analysis also considered chemical diversity, predicted binding affinity and interactions in the TYK2 pseudokinase binding pocket.
Reported benchmark result
The original case study reports approximately 75% of the 20 known actives ranked within the top 7% of the final 500,000-compound hit list, compared with approximately 43% using AutoDock Vina.
These are source-reported ranking results for this benchmark. The public account does not fully describe comparator settings, sampling uncertainty or prospective validation; it does not establish universal pipeline superiority.
Chemical and property analysis
The study describes structurally diverse hits, including previously unreported substructures and scaffolds with predicted interactions in the pseudokinase pocket. Some candidates were reported to have stronger predicted binding affinity than the comparator deucravacitinib.
A subset was predicted to cross the blood–brain barrier (BBB), but these candidates were relatively scarce in the shortlist. Predicted permeability requires experimental confirmation.
Next steps
The original research proposes earlier integration of BBB prediction and exploration of a larger initial database. Further optimization and validation would be needed to establish the properties of any resulting inhibitors.